Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial.
Imai M, Nakamura Y, Shin S, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Sawada K, Sato A, Kuwata T, Yamashita R, Fujisawa T, Bando H, Ock CY, Fujii S, Yoshino T. Imai M, et al. Among authors: yoshino t. JCO Precis Oncol. 2025 Jan;9:e2400385. doi: 10.1200/PO-24-00385. Epub 2025 Jan 17. JCO Precis Oncol. 2025. PMID: 39823559 Free PMC article. Clinical Trial.
The real prevalence and clinical courses of non-metastatic castration-resistant prostate cancer: a retrospective single-institutional study.
Takamori H, Goto T, Kashima S, Yoshino T, Ogata T, Aizawa R, Nakamura K, Sano T, Sawada A, Akamatsu S, Yamasaki T, Inoue T, Mizowaki T, Ogawa O, Kobayashi T. Takamori H, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2025 Jan 17:hyaf002. doi: 10.1093/jjco/hyaf002. Online ahead of print. Jpn J Clin Oncol. 2025. PMID: 39820449
Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.
Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, Rodriguez J, Chau I, Di Bartolomeo M, Kawakami H, Suto F, Koga M, Inaki K, Kuwahara Y, Takehara I, Barrios D, Kobayashi K, Grothey A, Yoshino T. Siena S, et al. Among authors: yoshino t. Nat Commun. 2025 Jan 15;16(1):704. doi: 10.1038/s41467-025-56170-9. Nat Commun. 2025. PMID: 39814812 Free PMC article. No abstract available.
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer.
Strickler JH, Bekaii-Saab T, Cercek A, Heinemann V, Nakamura Y, Raghav K, Siena S, Tabernero J, Van Cutsem E, Yoshino T, Ramos J, Guan X, Andre T. Strickler JH, et al. Among authors: yoshino t. Future Oncol. 2024 Dec 26:1-9. doi: 10.1080/14796694.2024.2441101. Online ahead of print. Future Oncol. 2024. PMID: 39723627 Free article.
2,113 results